The Cooper Cos. (NYSE:COO)’s share price traded down 1% during trading on Friday . The stock traded as low as $182.27 and last traded at $183.52, with a volume of 303,957 shares changing hands. The stock had previously closed at $185.37.

Several equities analysts have commented on the stock. BMO Capital Markets raised their price target on shares of The Cooper Cos. from $199.00 to $206.00 and gave the company an “outperform” rating in a research report on Friday. Stifel Nicolaus reissued an “in-line” rating on shares of The Cooper Cos. in a research report on Friday. Jefferies Group raised their price target on shares of The Cooper Cos. from $190.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, August 24th. Robert W. Baird raised their price target on shares of The Cooper Cos. from $185.00 to $196.00 and gave the company an “outperform” rating in a research report on Thursday, August 18th. Finally, Zacks Investment Research cut shares of The Cooper Cos. from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. Five research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $177.70.

The company has a 50 day moving average of $181.74 and a 200 day moving average of $163.78. The company has a market cap of $9.01 billion and a PE ratio of 43.98.

The Cooper Cos. (NYSE:COO) last announced its earnings results on Thursday, September 1st. The medical device company reported $2.30 EPS for the quarter, topping the consensus estimate of $2.29 by $0.01. The firm earned $514.70 million during the quarter. During the same period last year, the firm posted $1.97 EPS. The Cooper Cos.’s revenue for the quarter was up 11.5% on a year-over-year basis. Equities research analysts predict that The Cooper Cos. will post $8.43 earnings per share for the current fiscal year.

The company also recently announced a semiannual dividend, which was paid on Friday, August 5th. Shareholders of record on Friday, July 22nd were issued a $0.03 dividend. This represents a dividend yield of 0.03%. The ex-dividend date of this dividend was Wednesday, July 20th.

In other The Cooper Cos. news, EVP Carol R. Kaufman sold 49,500 shares of the firm’s stock in a transaction dated Tuesday, June 7th. The shares were sold at an average price of $163.92, for a total value of $8,114,040.00. Following the completion of the transaction, the executive vice president now directly owns 52,050 shares in the company, valued at $8,532,036. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gary S. Petersmeyer sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, June 14th. The stock was sold at an average price of $162.51, for a total transaction of $487,530.00. Following the completion of the transaction, the director now owns 4,715 shares of the company’s stock, valued at $766,234.65. The disclosure for this sale can be found here.

An institutional investor recently raised its position in The Cooper Cos. stock. I.G. Investment Management LTD. increased its position in The Cooper Cos. (NYSE:COO) by 40.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 30,760 shares of the medical device company’s stock after buying an additional 8,884 shares during the period. I.G. Investment Management LTD. owned approximately 0.06% of The Cooper Cos. worth $4,128,000 as of its most recent SEC filing.

The Cooper Companies, Inc (Cooper) is a medical device company. The Company operates through two business units: CooperVision, Inc (CooperVision) and CooperSurgical, Inc (CooperSurgical). CooperVision develops, manufactures and markets a range of soft contact lenses for the vision correction market. CooperVision offers Biofinity monthly spherical, toric and multifocal lenses under the Avaira brand.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.